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Abstract
Background: Endometrial carcinoma is the most common gynaecologic malignancy in industrialised countries and
the incidence is still rising. Primary treatment is based on preoperative risk classification and consists in most cases
of hysterectomy with bilateral salpingo-oophorectomy. In patients with serous and clear cell histology a complete
surgical staging is mandatory. However, in routine clinical practice final histology regularly does not correspond
with the preoperative histological diagnosis. This results in both over and under treatment.
Methods/Design: The aim of this multicentre, prospective cohort study is to select a panel of prognostic biomarkers
to improve preoperative diagnosis of endometrial carcinoma in order to identify those patients that need extended
surgery and/or additional treatment. Additionally, we will determine whether incorporation of cervical cytology and
comorbidity could improve this preoperative risk classification. All patients treated for endometrial carcinoma in the
participating hospitals from September 2011 till December 2013 are included. Patient characteristics, as well as
comorbidity are registered. Patients without preoperative histology, history of hysterectomy and/or endometrial
carcinoma or no surgical treatment including hysterectomy are excluded. The preoperative histology and final
pathology will be reviewed and compared by expert pathologists. Additional immunohistochemical analysis of
IMP3, p53, ER, PR, MLH1, PTEN, beta-catenin, p16, Ki-67, stathmin, ARID1A and L1CAM will be performed. Preoperative
histology will be compared with the final pathology results. Follow-up will be at least 24 months to determine risk
factors for recurrence and outcome.
Discussion: This study is designed to improve surgical treatment of endometrial carcinoma patients. A total of 432
endometrial carcinoma patients were enrolled between 2011 and 2013. Follow-up will be completed in 2015.
Preoperative histology will be evaluated systematically and background endometrium will be classified. This is
the first study incorporating immunohistochemistry, cervical cytology and comorbidity to define the optimal panel of
prognostic biomarkers that contribute in clinical decision making in the management of endometrial carcinoma.
Trial registration: Netherlands Trial Register number NTR3503
Keywords: Endometrial carcinoma, Histological diagnosis, Endometrial sampling, Postmenopausal bleeding,
Observational cohort study, Risk assessment
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Background
Endometrial carcinoma (EC) is the most common
gynaecologic malignancy in the United States with ap-
proximately 52,630 diagnosed cases annually [1]. In the
Netherlands the incidence is about 1900 women, with a
mortality rate of 480 [2]. The incidence is still rising due
to increased life expectancy and obesity as important
risk factor [3]. Although the majority of patients are
diagnosed at an early stage with a favourable prognosis,
still around 20 % of patients die from the disease [4].
ECs are staged according to the 2009 Fédération
Internationale de Gynécologie et d’Obstétrique (FIGO)
classification. ECs are divided into two types. The majority
of ECs are classified as type I and are related to unopposed
oestrogenic stimulation resulting from obesity or exogen-
ous hormone use and originate from hyperplastic endo-
metrium. This tumour type is associated with early stage
disease, endometrioid histology, and a favourable outcome
after surgery [5]. In contrast, type II carcinomas are unre-
lated to oestrogenic stimulation and arise in a background
of atrophic endometrium. Type II carcinomas are associ-
ated with advanced stage, high grade, non-endometrioid
histology, and an overall a poor prognosis [5]. A recent
study suggests the existence of a third type of EC charac-
terised by low grade endometrioid endometrial carcinoma
(EEC) and a background of atrophic endometrium [6].
This third type of EC may have a poorer prognosis when
compared to type I carcinomas [6]. However, recently
published data of The Cancer Genome Atlas (TCGA)
Research Network, identified four subgroups of EC based
on molecular classifiers such as TP53, PTEN and micro-
satellite instability [7]. This supports the need for adjusting
the currently used classification.
Primary treatment
Primary treatment is currently based on preoperative
risk classification and consists of hysterectomy with bi-
lateral salpingo-oophorectomy. In uterine papillary ser-
ous carcinoma (UPSC) and clear cell carcinoma (CCC) a
complete surgical staging is mandatory because of the
high risk of extra-uterine disease [8–10]. Although the
presence of lymph node metastasis is an unfavourable
predictor for disease specific survival, data of Kwon
et al. demonstrated that high-risk uterine factors includ-
ing high grade tumour type, deep myometrial invasion,
and cervical stromal involvement are more significant
determinants of survival in EC than pelvic-node status
[11]. The current study focuses on diagnosis and pre-
operative risk assessment of patients with EC.
Preoperative diagnosis
During the last decades dilatation and curettage (D&C)
has been replaced by minimally invasive techniques
for endometrial sampling in an outpatient setting. The
amount of tissue obtained from endometrial sampling is
relatively small and there can be different subtypes of
EC in one tumour, making routine histological discrim-
ination between EEC and a high grade, UPSC or CCC
difficult. Moreover, in 30 % the amount of tissue obtained
with outpatient endometrial sampling is insufficient for
diagnosis [12]. Previous studies found discrepancy per-
centages between 15 and 40 %, including both grade and
histological subtype [13–17]. When preoperative diagnosis
was based on D&C or endometrial sampling, a preopera-
tive diagnosis of grade 1 was concordant with the final
diagnosis in 85 % of cases. However, high grade lesions
were more frequently underestimated by endometrial
sampling compared to D&C [18].
Immunohistochemical analysis in preoperative
endometrial sampling
Identification of a panel of immunohistochemical (IHC)
markers may be helpful to establish a reliable preopera-
tive risk classification. A brief summary of the selected
markers that will be tested is given in Table 1. P53
immunopositivity is associated with non-endometrioid
EC [19]. Negative IHC for oestrogen and progesterone
receptors can predict lymph node metastasis and is asso-
ciated with decreased survival [20]. Double negative
hormone receptor status and p53 immunopositivity cor-
relates with lymph node metastasis, high FIGO stage,
non-endometrioid histology, high grade and poor
prognosis [20]. Insulin-like growth factor II messenger
RNA-binding protein 3 (IMP3) is a foetal protein not
expressed in normal adult tissues. This oncoprotein
plays an important role in tumour growth, migration
and invasion. IMP3 could contribute to the preoperative
identification of type II tumours, since it is more fre-
quently expressed in UPSC and CCC when compared to
EEC (resp. 78 %, 57 % and 15 %) [21]. A recent study
showed that L1CAM is the best predicting prognostic
factor in FIGO stage I, type I EC and superior to the
standard used multifactor risk score (myometrial in-
vasion, tumour grade and lymph space or vascular
invasion) [22]. L1CAM immunohistochemistry can im-
prove the identification of patients at risk for recurrent
disease. However, all the mentioned biomarkers are lack-
ing validation on pre-operative histological samples and
are based on singles studies. Further research has to val-
idate these promising results.
Preoperative diagnosis of EC in cervical cytology
The presence of endometrial cells in cervical cytology in
postmenopausal women is strongly associated with
endometrial pathology [23]. Abnormal cervical cytology
is associated with extra-uterine disease in patients
with UPSC and with cervical involvement in patients
with EEC [24]. A combination of preoperative cervical
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cytology with endometrial sampling might better predict
final histology and risk for extended disease. In a study of
Kinde et al. DNA was extracted from cervical smears to
detect genetic disorders present in EC [25]. The mutation
profile found in the primary tumour was found in all of
the cervical smears [25]. These results indicate that cer-
vical cytology might be a reliable and minimal invasive
source of material for detection of EC.
Comorbidity and EC
The impact of comorbidity on cancer outcome has been
underestimated for a long time. Recently published data
demonstrated that EC patients with cardiovascular dis-
ease, previous malignancy and diabetes have a signifi-
cantly decreased survival of 15–17 % compared to
patients without comorbidity [26]. Additionally, patients
with diabetes and EC have more comorbidities, higher
body mass index (BMI) and higher FIGO stage, com-
pared to those without diabetes [27]. There is also a sig-
nificant increase in the risk of EC-specific mortality
among women with diabetes [28]. Although obesity is a
risk factor for development of EC, obesity seems not
related to overall survival [29]. Yet, comorbidity has
demonstrated to influence the outcome in EC [30].
In summary, the main challenging issue concerning
clinical management of EC patients is underscored by
the discordance between the preoperative risk classifica-
tion of the tumour and the final surgical pathology. At
the moment a subgroup of patients needs either a sec-
ondary surgical staging procedure or additional chemo-
therapy and/or radiation therapy. With the current study
we want to select a panel of the most accurate bio-
markers that can be used in daily practice for preopera-
tive diagnosis of EC. This will aid in improving the
concordance between preoperative and final histological
diagnosis and thus prevent over and under treatment.
Incorporating cervical cytology and comorbidity could
potentially improve a proper risk classification in EC
patients.
Methods/Design
Objective
Primary objective
To determine whether standardized evaluation of endo-
metrial biopsies with additional immunohistochemical
analysis, could predict final histological type, tumour
grade and stage.
Secondary objective
To determine whether additional immunohistochemical
analysis on endometrial biopsies could predict recur-
rence and disease free survival. Additionally, to determine
Table 1 Immunohistochemical analysis
Immunohistochemical marker Results Ref.
IMP3 Insulin-like growth factor II mRNA-binding protein 3 IMP3 is more frequently expressed in UPSC and CCC than in EEC
(resp. 78 %, 57 % and 15 % of the tumours were positive).
[21]
P53 P53 is more expressed in non-endometrioid endometrial
carcinomas than in EEC. Expression is also related to higher
tumour grade.
[19]
ER and PR Oestrogen and progesterone receptor Negative receptors were associated with lymph node metastasis
and decreased survival. ER and PR expression is lower in
non-endometrioid endometrial carcinomas than in EEC.
[20, 34]
MLH1 MutL homolog 1 Loss of expression of mismatch repair proteins is seen in high
grade EEC and not in UPSC and CCC. Loss of MLH1 expression
is associated with longer survival.
[35, 36]
PTEN Phosphatase and tensin homologue PTEN positivity is more frequently found in UPSC than EEC. [19]
Beta-catenin Positive beta-catenin expression is associated with decreased
stage, decreased grade and negative lymph node status
[37]
P16 Loss of p16 expression is significantly correlated with high FIGO
stage and serous and clear cell histological subtype.
[38]
Ki-67 Higher Ki-67 expression is associated with higher tumour grade.
UPSC and CCC show higher Ki-67 proliferation index than EEC.
[34]
Stathmin Stathmin overexpression was associated with non-endometrioid
histology, high grade and poor disease-specific survival.
[39]
ARID1A AT-rich interactive domain 1A gene Loss of ARID1A expression is significantly more frequent in high
grade EEC compared to UPSC.
[40]
L1CAM L1 cell adhesion molecule L1CAM is associated with higher grade and non-endometrioid
histology. Moreover, L1CAM positive EC have statistical significant
poorer disease-free survival and overall survival.
[22]
UPSC = Uterine papillary serous carcinoma; CCC = Clear Cell Carcinoma; EEC = Endometrioid endometrial carcinoma; EC = endometrial carcinoma; FIGO = Fédération
Internationale de Gynécologie et d’Obstétrique
Visser et al. BMC Cancer  (2015) 15:487 Page 3 of 6
whether incorporation of abnormal cervical cytology and
comorbidity attributes to an improved risk classification.
Study design
Multicentre, prospective cohort study in nine hospitals
in the Netherlands. From September 1st 2011 till
December 1st 2013 all patients treated for EC in partici-
pating hospitals are included. Patients without preopera-
tive histology, history of hysterectomy and/or endometrial
carcinoma or no surgical treatment including hysterec-
tomy are excluded. Patient characteristics, as well as
comorbidity (Charlson index), BMI, family history of her-
editary syndromes (BRCA1/2, Lynch syndrome), postmen-
opausal status and parity are registered. Based on the
present comorbidities, all patients are assigned a comor-
bidity score based on the Age-Adjusted Comorbidity-
index as described by Charlson et al. [31], with EC being
excluded from the scoring. Treatment and final patho-
logical diagnosis are registered as well as occurrence of
recurrent disease during at least 24 months follow-up.
Tissue specimens
The endometrial biopsy or curettage on which the
diagnosis of EC was made will be used for systematic
evaluation by pathologists with special interest in gynae-
cologic pathology. Additional IHC analysis of IMP3, p53,
ER, PR, MLH1, PTEN, beta-catenin, p16, Ki-67, stath-
min, ARID1A and L1CAM will be performed (Table 1).
Final pathology will be reviewed by the expert patholo-
gists and compared with the preoperative histological
diagnosis. The pathologists will be blinded for clinico-
pathological information and outcome.
Methods
Tissue specimens are collected centrally at the depart-
ment of Pathology, Radboud university medical centre in
Nijmegen. Pre-operative samples will be evaluated on
the amount of tissue (quantitatively and qualitatively),
the presence of hyperplasia, atypia, endometrial intrae-
pithelial carcinoma (EIC), invasive growth, background
endometrium, tumour percentage and tumour type and
grade. IHC staining will be performed on formalin-fixed,
paraffin-embedded tissue of the pre-operative samples.
IHC staining will be graded semiquantitatively by con-
sidering the percentage and intensity of the staining. A
staining index will be calculated as the product of stain-
ing intensity and staining area.
Statistical analysis
For the primary objective, results of endometrial biopsy
and curettage will be compared with final pathology re-
sults. Both univariate as well as multivariate analysis will
be performed to determine whether immunohistochemi-
cal markers contribute to prediction of final pathology.
For the secondary objective we will also include abnormal
cervical cytology and the Age-Adjusted Comorbidity-index
as factors in univariate and multivariate analysis. In order
to determine risk factors for recurrence Kaplan-Meier sur-
vival curves will be calculated to determine outcome after
a follow-up time of 24 months. Statistical analysis will be
performed using the Statistical and Data management
package SPSS 20.0.
Sample size calculation
Calculation of the sample size is based on the primary
outcome variable of the study, which is high risk endo-
metrial carcinoma. The smallest outcome group, in this
case patients with high risk endometrial carcinoma,
should be 10–20 times the amount of independent vari-
ables used.
Independent variables in the analyses will be: age
(dichotomous), grade (1, 2 and 3) and the best predictive
immunohistochemical markers. For the sample size cal-
culation we assume to include six immunohistochemical
markers in the multivariate analysis. Grade count as two
variables because we use it as a trichotomous variable,
which makes the total variables nine.
Table 2 Clinicopathological characteristics of 432 women with
endometrial carcinoma. Values are presented as median (range)
or number (%)
Characteristics
Age at primary surgery, years 66 (41–90)
Pre-operative histologya
Office endometrial biopsy 311 (72.0)
Hysteroscopic biopsy 128 (29.6)
Curettage 75 (17.4)
Histological subtypeb
Endometrioid 370 (85.6)
Serous papillary 33 (7.6)
Clear cell 9 (2.1)
Mucinous adenocarcinoma 2 (0.5)
Carcinosarcoma 18 (4.2)
Histological gradeb
1 193 (44.7)
2 127 (29.4)
3 112 (25.9)
FIGO 2009 stage
I 362 (83.8)
II 27 (6.3)
III 35 (8.1)
IV 8 (1.9)
a 82 patients have more than one pre-operative histological sample
b Unrevised classification based on hysterectomy specimen
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The amount of subjects in the smallest group therefore
should lie between 90 and 180. However, as a rule of
thumb, the amount of subjects should never be lower
than 100.
With an expected high risk endometrial carcinoma
rate of 25 % at least 400 patients with endometrial car-
cinoma should be included to include at least 100 pa-
tients with high risk endometrial carcinoma.
Ethical considerations
This study is approved by the local medical ethical com-
mittee of the St Elisabeth Hospital Tilburg. According to
the protocol “Code for Proper Use of Human Tissue”, all
collected patient material will be coded, and patient
name and date of birth are not entered into the database
(Dutch Federation for Biomedical Scientific Societies,
www.federa.org). We did not obtain written informed
consent from patients because we use data anonym-
ously according to the “Code for Proper Use of Human
Tissue”. Included patients are informed about tissue
and data use for scientific purpose in general and made
no drawbacks.
Discussion
A total of 432 EC patients from nine hospitals were col-
lected between September 2011 and December 2013.
The inclusion of patients has finished and we are now
analysing the data. Follow-up will be completed in
December 2015. The various histological subtypes of EC
are all represented in this study group with 86 % EEC,
8 % UPSC and 2 % CCC based on hysterectomy evalu-
ation. This is in line with percentages reported in the
Netherlands Cancer Registry [32]. Clinicopathological
characteristics are shown in Table 2. Atypical hyperplasia
is diagnosed in 13 % of the preoperative endometrial
samples, where final diagnosis on hysterectomy was EC.
We will determine if a diagnostic panel of IHC
markers can improve the preoperative diagnosis for risk
selection. This is the first study combining L1CAM with
other markers to find the optimal panel of biomarkers
for the preoperative diagnosis of EC. The additional
value of immunohistochemical analysis in EC has been
demonstrated in the large multicentre MoMaTEC trial
[20], yet, this study focussed on predicting lymph node
metastasis and prognosis in relation to treatment. Our
focus is on preoperative risk classification with respect
to histological type and tumour grade. Preoperative and
final surgical pathology will be revised by expert pathol-
ogists. Furthermore, preoperative biopsy and curettage
will be evaluated systematically, and compared with final
histology. Additionally, background endometrium will be
classified as: atrophic endometrium, hyperplastic endo-
metrium, normal proliferative endometrium or indeter-
minate. Since, in a previous study on hysterectomy
specimens, atrophic background endometrium was found
to be an independent prognostic factor for patients with
grade 1 EEC [6]. To date, no studies on the prognostic
value of background endometrium in preoperative endo-
metrial sampling are published.
Due to tumour heterogeneity and focal staining pat-
terns, IHC on endometrial biopsies may not always be
representative for the whole tumour. Most studies on
IHC in endometrial carcinomas were performed on hys-
terectomy specimens. Yet, our clinical challenge is to
select high risk tumour preoperatively on a limited
amount of material. Our study design represents daily
practice and with this study we will determine whether
additional IHC analysis could predict final histology.
Huang et al. reported comparable sensitivity for detect-
ing high grade EC with Pipelle versus curettage [33].
The predictive value between endometrial biopsies and
curettage might be different when IHC is applied, and
hence influence outcome. To date, there are no studies
on the influence of IHC on the difference in predictive
value between biopsy and curettage. By using IHC the
difference in the amount of material collected by biopsy
and curettage might become relevant. Interestingly, in-
corporation of comorbidity in the preoperative risk clas-
sification has not been studied so far.
Summarizing, systematic preoperative evaluation of
both tumour and patient characteristics could give max-
imal information and result in patient tailored treatment
in patients with EC.
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